Overview

A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL

Status:
RECRUITING

Trial end date:
2029-04-30

Target enrollment:

Participant gender:

Summary

A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL

Phase:

PHASE1

Details

Lead Sponsor:

Ono Pharmaceutical Co. Ltd